{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:24:59Z","timestamp":1773008699914,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1007\/s11892-002-0103-5","type":"journal-article","created":{"date-parts":[[2007,8,30]],"date-time":"2007-08-30T09:51:56Z","timestamp":1188467516000},"page":"396-402","source":"Crossref","is-referenced-by-count":16,"title":["Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes"],"prefix":"10.1007","volume":"2","author":[{"given":"Milagros G.","family":"Huerta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry L.","family":"Nadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"103_CR1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115\u2013126. Review of the inflammatory mechanisms that contribute to the development and progression of atherosclerosis.","journal-title":"N Engl J Med"},{"key":"103_CR2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/diab.44.4.369","volume":"44","author":"MP Stern","year":"1995","unstructured":"Stern MP: Diabetes and cardiovascular disease: the \"common soil\" hypothesis. Diabetes 1995, 44:369\u2013374.","journal-title":"Diabetes"},{"key":"103_CR3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","volume":"286","author":"AD Pradhan","year":"2001","unstructured":"Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6 and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327\u2013334. Demonstrated that elevated CRP is a powerful independent predictor of risk for T2DM.","journal-title":"JAMA"},{"key":"103_CR4","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2337\/diacare.23.12.1835","volume":"23","author":"M Fr\u00f6hlich","year":"2000","unstructured":"Fr\u00f6hlich M, Imhof A, Berg G, et al.: Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 2000, 23:1835\u20131839.","journal-title":"Diabetes Care"},{"key":"103_CR5","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1152\/ajpendo.2001.280.5.E745","volume":"280","author":"PA Kern","year":"2001","unstructured":"Kern PA, Ranganathan S, Li C, et al.: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-E751.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"103_CR6","first-page":"3338","volume":"85","author":"JP Bastard","year":"2000","unstructured":"Bastard JP, Jardel C, Bruckert E, et al.: Elevated levels of interleukin 6 are reduced in serum and adipose tissue of obese women after weight loss. J Clin Endocrinol Metabol 2000, 85:3338\u20133342.","journal-title":"J Clin Endocrinol Metabol"},{"key":"103_CR7","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1001\/jama.282.22.2131","volume":"282","author":"M Visser","year":"2000","unstructured":"Visser M, Bouter LM, McQuillan GM, et al.: Elevated C-reactive protein levels in overweight and obese adults. JAMA 2000, 282:2131\u20132135.","journal-title":"JAMA"},{"key":"103_CR8","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.ATV.19.4.972","volume":"19","author":"JS Yudkin","year":"1999","unstructured":"Yudkin JS, Stehouwer CDA, Emeis JJ, et al.: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999, 19:972\u2013978.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"103_CR9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","volume":"102","author":"A Festa","year":"2000","unstructured":"Festa A, D'Agostino RJ, Howard G, et al.: Chronic subclinical inflammation as part of insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42\u201347.","journal-title":"Circulation"},{"issue":"suppl 3","key":"103_CR10","first-page":"16","volume":"23","author":"J Girard","year":"1997","unstructured":"Girard J: Is leptin the link between obesity and insulin resistance? Diabetes Metab 1997, 23(suppl 3):16\u201324.","journal-title":"Diabetes Metab"},{"key":"103_CR11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/39335","volume":"389","author":"KT Uysal","year":"1997","unstructured":"Uysal KT, Wiesbrock SM, Marino MW, et al.: Protection from obesity-induced insulin resistance in mice lacking TNF alpha function. Nature 1997, 389:610\u2013614.","journal-title":"Nature"},{"key":"103_CR12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/eje.0.1450273","volume":"145","author":"M Straczkowski","year":"2001","unstructured":"Straczkowski M, Kowalska I, Dzienis-Straczkowska S, et al.: Changes in tumor necrosis factor-alpha system and insulin sensitivity during an exercise training program in obese women with normal and impaired glucose tolerance. Eur J Endocrinol 2001, 145:273\u2013280.","journal-title":"Eur J Endocrinol"},{"key":"103_CR13","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(99)01046-6","volume":"353","author":"MI Schmidt","year":"1999","unstructured":"Schmidt MI, Duncan BB, Sharrett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 1999, 353:1649\u20131652.","journal-title":"Lancet"},{"key":"103_CR14","doi-asserted-by":"crossref","first-page":"E323","DOI":"10.1152\/ajpcell.1995.269.2.C323","volume":"269","author":"MG O'Riordain","year":"1995","unstructured":"O'Riordain MG, Ross JA, Fearon KC, et al.: Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol 1995, 269:E323-E330.","journal-title":"Am J Physiol"},{"key":"103_CR15","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.2337\/diabetes.50.10.2384","volume":"50","author":"JI Barzilay","year":"2001","unstructured":"Barzilay JI, Abraham L, Heckbert SR, et al.: The relation of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50:2384\u20132389.","journal-title":"Diabetes"},{"key":"103_CR16","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/diabetes.51.4.1131","volume":"51","author":"A Festa","year":"2002","unstructured":"Festa A, D'Agostino RJ, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002, 51:1131\u20131137. Demonstrated that elevated PAI-1 is a good predictor of T2DM independent of IR and other known risk factors.","journal-title":"Diabetes"},{"key":"103_CR17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/01.CIR.100.11.1148","volume":"100","author":"P Libby","year":"1999","unstructured":"Libby P, Ridker P: Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999, 100:1148\u20131150.","journal-title":"Circulation"},{"key":"103_CR18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","volume":"103","author":"DJ Freeman","year":"2001","unstructured":"Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357\u2013362.","journal-title":"Circulation"},{"key":"103_CR19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","volume":"353","author":"RS Rosenson","year":"1999","unstructured":"Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999, 353:983\u2013984.","journal-title":"Lancet"},{"key":"103_CR20","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","volume":"286","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882\u20131885. Showed a 34% risk reduction for new-onset T2DM in the group treated with ramipril compared with placebo.","journal-title":"JAMA"},{"key":"103_CR21","first-page":"R332","volume":"277","author":"EJ Henriksen","year":"1999","unstructured":"Henriksen EJ, Jacob S, Kinnick TR, et al.: ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. A J Physiol 1999, 277:R332-R336.","journal-title":"A J Physiol"},{"key":"103_CR22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00500383","volume":"34","author":"E Torlone","year":"1991","unstructured":"Torlone E, Rambotti AM, Perriello G, et al.: ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991, 34:119\u2013125.","journal-title":"Diabetologia"},{"issue":"suppl 2","key":"103_CR23","first-page":"A35","volume":"51","author":"T Buchanan","year":"2002","unstructured":"Buchanan T, Xiang A, Peters R, et al.: Prevention of type 2 diabetes by treatment of insulin resistance: comparison of early vs. late intervention in the TRIPOD study. Diabetes 2002, 51(suppl 2):A35.","journal-title":"Diabetes"},{"issue":"suppl 2","key":"103_CR24","first-page":"A137","volume":"51","author":"JW Chu","year":"2002","unstructured":"Chu JW, Abbasi F, Lamendola C, et al.: Rosiglitazone enhances insulin sensitivity and decreases cardiovascular risk factors in insulin-resistant subjects without diabetes mellitus. Diabetes 2002, 51(suppl 2):A137.","journal-title":"Diabetes"},{"key":"103_CR25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/diacare.22.2.280","volume":"22","author":"T Konrad","year":"1999","unstructured":"Konrad T, Vicini P, Kusterer K, et al.: alpha-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese type 2 diabetes. Diabetes Care 1999, 22:280\u2013287.","journal-title":"Diabetes Care"},{"issue":"suppl 2","key":"103_CR26","first-page":"A386","volume":"51","author":"Z Yang","year":"2002","unstructured":"Yang Z, Chen M, Fialkow LB, et al.: Protection of cytokinemediated apoptosis in human pancreatic islets by lisofylline. Diabetes 2002, 51(suppl 2):A386.","journal-title":"Diabetes"},{"key":"103_CR27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0002-9343(01)00978-0","volume":"111","author":"ES Huang","year":"2001","unstructured":"Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patient with type 2 diabetes mellitus. Am J Med 2001, 111:633\u2013642.","journal-title":"Am J Med"},{"key":"103_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.322.7277.1","volume":"322","author":"KT Khaw","year":"2001","unstructured":"Khaw KT, Wareham N, Luben R, et al.: Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001, 322:1\u20136. Demonstrated that a lower value of hemoglobin A1c is associated with a lower CV risk even within the normal range for hemoglobin A1c.","journal-title":"BMJ"},{"key":"103_CR29","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1161\/01.CIR.102.18.2165","volume":"102","author":"V Pasceri","year":"2000","unstructured":"Pasceri V, Wilkerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165\u20132168.","journal-title":"Circulation"},{"key":"103_CR30","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1161\/01.CIR.103.13.1813","volume":"103","author":"PM Ridker","year":"2001","unstructured":"Ridker PM: High sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813\u20131818.","journal-title":"Circulation"},{"key":"103_CR31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bmj.321.7255.199","volume":"321","author":"J Danesh","year":"2000","unstructured":"Danesh J, Whincup P, Walker M, et al.: Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321:199\u2013204.","journal-title":"BMJ"},{"key":"103_CR32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2337\/diabetes.51.4.1157","volume":"51","author":"C Stehouwer","year":"2002","unstructured":"Stehouwer C, Gall MA, Twisk JWR, et al.: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated and independently associated with risk of death. Diabetes 2002, 51:1157\u20131165.","journal-title":"Diabetes"},{"key":"103_CR33","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Hennekens CH, Buring JE, et al.: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836\u2013843.","journal-title":"N Engl J Med"},{"key":"103_CR34","doi-asserted-by":"crossref","first-page":"933","DOI":"10.7326\/0003-4819-130-11-199906010-00018","volume":"130","author":"PM Ridker","year":"1999","unstructured":"Ridker PM: Physician's Health Study. Ann Intern Med 1999, 130:933\u2013937.","journal-title":"Ann Intern Med"},{"key":"103_CR35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","volume":"286","author":"MA Albert","year":"2001","unstructured":"Albert MA, Danielson E, Rifai N, et al.: Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation\/ CRP Evaluation (PRINCE): a randomized clinical trial and cohort study. JAMA 2001, 286:64\u201370. Found significant reductions in CRP during pravastatin treatment of patients with no prior history of CVD and LDL-C levels of at least 130 mg\/dL; this effect was not significantly related to pravastatin-induced changes in LDL-C.","journal-title":"JAMA"},{"key":"103_CR36","first-page":"1940","volume":"81","author":"A Antonipillai","year":"1996","unstructured":"Antonipillai A, Nadler J, Jost-Vu E, et al.: A 12-lipoxygenase product, 12-hydroxyeicosatetranoic acid is increased in diabetes with incipient and early renal disease. J Clin Endocrinol Metab 1996, 81:1940\u20131945.","journal-title":"J Clin Endocrinol Metab"},{"key":"103_CR37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/978-1-4615-4793-8_67","volume":"469","author":"CC Hedrick","year":"1999","unstructured":"Hedrick CC, Kim MD, Natarajan R, Nadler JL: 12-lipoxygenase products increase monocyte:endothelial interactions. Adv Exp Med Biol 1999, 469:455\u2013460.","journal-title":"Adv Exp Med Biol"},{"key":"103_CR38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s125-002-8253-x","volume":"45","author":"R Natarajan","year":"2002","unstructured":"Natarajan R, Gerrity RG, Gu JL, et al.: Role of 12-lipoxygenase and oxidant stress in hyperglycemia-induced acceleration of atherosclerosis in a diabetic pig model. Diabetologia 2002, 45:125\u2013133.","journal-title":"Diabetologia"},{"key":"103_CR39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s000110050622","volume":"49","author":"G Chinetti","year":"2000","unstructured":"Chinetti G, Fruchart JC, Staels B: Peroxisome proliferatoractivated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000, 49:497\u2013505.","journal-title":"Inflamm Res"},{"key":"103_CR40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/01.RES.0000014225.20727.8F","volume":"90","author":"N Marx","year":"2002","unstructured":"Marx N, Kehrle B, Kohlhammer K, et al.: PPAR activators as anti-inflammatory mediators in human t lymphocytes. Implications for atherosclerosis and transplantationassociated atherosclerosis. Circ Res 2002, 90:703\u2013710.","journal-title":"Circ Res"},{"key":"103_CR41","first-page":"203","volume":"4","author":"SJ Robins","year":"2001","unstructured":"Robins SJ: PPAR-alpha ligands and clinical trials: cardiovascular risk reduction with fibrates. J Cardiovasc Risk 2001, 4:203\u2013210.","journal-title":"J Cardiovasc Risk"},{"key":"103_CR42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.ATV.21.3.365","volume":"21","author":"AR Collins","year":"2001","unstructured":"Collins AR, Meehan WP, Kintscher U, et al.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:365\u2013371.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"103_CR43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00019501-200108000-00011","volume":"12","author":"S Rosenblatt","year":"2001","unstructured":"Rosenblatt S, Miskin B, Glazer NB, et al.: The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001, 12:413\u2013423.","journal-title":"Coron Artery Dis"},{"key":"103_CR44","first-page":"A149","volume":"50","author":"AE Caballero","year":"2001","unstructured":"Caballero AE, Saquaf R, Lim SC, et al.: The effects of troglitazone on the endothelial function of the micro and macrocirculation in patients with early or late type 2 diabetes. Diabetes 2001, 50:A149.","journal-title":"Diabetes"},{"key":"103_CR45","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1161\/01.CIR.103.21.2531","volume":"103","author":"V Pasceri","year":"2001","unstructured":"Pasceri V, Chang J, Willerson JT, Yeh ETH: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerosis drugs. Circulation 2001, 103:2531\u20132534.","journal-title":"Circulation"},{"key":"103_CR46","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","volume":"98","author":"RB Goldberg","year":"1998","unstructured":"Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucoseintolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998, 98:2513\u20132519.","journal-title":"Circulation"},{"key":"103_CR47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","volume":"98","author":"PM Ridker","year":"1998","unstructured":"Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998, 98:839\u2013844.","journal-title":"Circulation"},{"key":"103_CR48","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. JAMA 1998, 279:1615\u20131622.","journal-title":"JAMA"},{"key":"103_CR49","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepard","year":"1995","unstructured":"Shepard J, Cobb SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301\u20131307.","journal-title":"N Engl J Med"},{"key":"103_CR50","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/01.CIR.101.12.1372","volume":"101","author":"B Schieffer","year":"2000","unstructured":"Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al.: Expression of angiotensin ii and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000, 101:1372\u20131378.","journal-title":"Circulation"},{"key":"103_CR51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00041552-200105000-00005","volume":"10","author":"M Ruiz-Ortega","year":"2001","unstructured":"Ruiz-Ortega M, Lorenzo O, Suzuki Y, et al.: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001, 10:321\u2013329. Discusses the molecular mechanisms by which angiotensin II contributes to the proinflammatory pathways involved in the development of atherosclerosis, hypertension, and renal damage.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"103_CR52","doi-asserted-by":"crossref","unstructured":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. The SOLVD Investigators [no authors listed]. N Engl J Med 1992, 327:725-727.","DOI":"10.1056\/NEJM199209033271003"},{"key":"103_CR53","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"M Pfeffer","year":"1992","unstructured":"Pfeffer M, Braunwald E, Moye L, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992, 327:669\u2013677.","journal-title":"N Engl J Med"},{"key":"103_CR54","doi-asserted-by":"crossref","unstructured":"Effects of ramipril on cardiovascular and microvascular complications outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Study. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. Lancet 2000, 355:253-259.Demonstrated that ramipril treatment in patients with diabetes is associated with a reduction in CV events and mortality. This finding was only partially related to blood-pressure reduction, suggesting a direct vascular protective effect of ramipril.","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"103_CR55","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/01.CIR.103.7.919","volume":"103","author":"E Lonn","year":"2001","unstructured":"Lonn E, Yusuf S, Dzavik V, et al.: Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation 2001, 103:919\u2013925.","journal-title":"Circulation"},{"key":"103_CR56","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","volume":"359","author":"LH Lindholm","year":"2002","unstructured":"Lindholm LH, Ibsen H, Dahl\u00f6f B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004\u20131010.","journal-title":"Lancet"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-002-0103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-002-0103-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-002-0103-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:52:08Z","timestamp":1559433128000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-002-0103-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["103"],"URL":"https:\/\/doi.org\/10.1007\/s11892-002-0103-5","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}